Does PIII pay a dividend and is it safe?

P3 Health Partners Inc. (Class A) (PIII) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / PIII / dividends

DCGO (39) EUDA (39) ALPS (52) CCM (22) ⌘ Pro Terminal →

P3 Health Partners Inc. (Class A) (PIII) Dividend Safety Gauge & 10-Year DRIP Compounder

$4.00 -0.75% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.99

P3 Health Partners Inc. (Class A) (PIII) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $29.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PIII Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PIII stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, P3 Health Partners Inc. (Class A) (NASDAQ: PIII) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $4.00 (-0.75% 1D, market cap $29.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PIII ranks #942 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PIII compare to DCGO and EUDA in the Health Care sector?

▼

Within the Health Care sector (Medical/Nursing Services), PIII carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DCGO (DocGo Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $24.4M) and EUDA (EUDA Health Holdings Limited) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $53.0M). Among the 5-stock peer group, PIII leads on earnings multiple (N/A) while PIII leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PIII?

▼

Per PIII's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001832511), P3 Health Partners Inc. (Class A) generated $1.46B in revenue (-2.8% YoY), -$147.9M in net income, and -$91.2M in free cash flow against $656.6M in total assets and $228.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.99 (-0.33%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (24/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-15.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PIII)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (24/100 Composite)

🔍 WHY PIII SCORES 24/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+8/20 pts (33% of score)

FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 33.9 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$4.03-1.5% Next Q

Q2 (-2Q)

Grade E$3.97-4% Next Q

Q3 (-1Q)

Grade E$3.81+5% Next Q

Current

Grade E$4.00-10.9% Hist 90D α

Trajectory: E (32) → E (24)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PIII Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PIII currently carries a cautious 24/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.50) and Max Pain ($4.20) forces dealer call-delta covering toward $17.73.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PIII• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PIII Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 24%NO 76%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PIII)

✓Walkthrough of PIII's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PIII // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +40.35%🛡️ HOLDING TREND SUPPORT

2026-11-03O $4.20H $4.20L $4.00C $4.00VOL 19.7K

RES: $10.14SUP: $3.31SMA50: $6.50SMA200: $6.55

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PIII Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PIII Butterfly Map → + Track PIII →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -2.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PIII today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PIII. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PIII today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PIII)

Health Care Rank #942 of 1015 ⚔️ DCGO vs PIII Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PIII vs. DCGO, EUDA, ALPS, CCM)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, P3 Health Partners Inc. (Class A) (PIII) ranks #942 by composite RQD confidence (24/100, grade E) and #802 by equity capitalization ($29.3M). Within this direct 5-issuer industry benchmark cohort, PIII leads on earnings valuation at N/A trailing P/E, while PIII leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ALPS currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with PIII at 24/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PIII ACTIVE P3 Health Partners Inc. (Class A)	E	24/100	—	—	-35.0%	-0.75%	$29.3M	Benchmark Subject
DCGO DocGo Inc.	D-	39/100	—	—	-35.0%	-13.32%	$24.4M	/dcgo-vs-piii →
EUDA EUDA Health Holdings Limited	D-	39/100	—	43.9%	-35.0%	-12.03%	$53.0M	/euda-vs-piii →
ALPS ALPS Group Inc Ordinary Share	D+	52/100	—	—	—	-0.21%	$54.1M	/alps-vs-piii →
CCM Concord Medical Services Holdings Limited (Each represents thirty (30) ) (Class A)	E	22/100	—	5.7%	-35.0%	+0.56%	$15.5M	/ccm-vs-piii →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001832511 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), P3 Health Partners Inc. (Class A) (PIII) reported GAAP revenue of $1.46B (-2.8% vs. FY2024 revenue of $1.50B , and +15.2% cumulative change since FY2023) , GAAP net income of -$147.9M, operating cash flow of -$91.2M, and free cash flow of -$91.2M (+17.2% YoY). On the balance sheet, PIII closed FY2025 with $656.6M in total assets against $228.4M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.46B	-$147.9M	-$91.2M	-$91.2M	$656.6M	$228.4M
FY2024 (FY)	2024-12-31	$1.50B	-$135.8M	-$110.1M	-$110.1M	$783.4M	$108.9M
FY2023 (FY)	2023-12-31	$1.27B	-$57.8M	-$76.0M	-$76.0M	—	—

3. PIII Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PIII stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PIII compare to DCGO and EUDA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PIII?

Where is PIII trading relative to its 50-day, 200-day, and 52-week technical levels?

PIII last traded at $4.00 (-0.75% on volume of 7,351 shares), positioning the stock -38.46% below its 50-day simple moving average ($6.50) and -38.93% below its 200-day simple moving average ($6.55). Across its 52-week range of $1.52 to $16.89, PIII sits at the 16.1% percentile with a 14-day RSI of 33.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.50 to $4.50).

Direct Sub-Reports: PIII RQD Cockpit PIII 12M Forecast PIII Earnings & Move PIII Dividends & DRIP PIII Insiders & 13F PIII Whale Options PIII Profit Sankey PIII News & Why

ROARABLE RATING BRIEF • RQD 24/100 (E) ✓ SEC XBRL & RQD VERIFIED

PIII — P3 Health Partners Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

P3 Health Partners Inc. (Class A) (PIII) earns a live Roarable RQD composite score of 24/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.00 (-0.75% 1D, market capitalization $29.3M).

Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -18.5%, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (8/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

P3 Health Partners Inc. (Class A) (PIII) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Nursing Services industry.. — describes its specific products, customer base, or revenue model beyond this classification.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), P3 Health Partners Inc. (Class A) (PIII) reported $1.46B in annual revenue (up from $1.50B in FY2024, -2.8% YoY) and -$147.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.27B revenue, -$57.8M net income) through FY2025, PIII scaled operating cash flow to -$91.2M and free cash flow to -$91.2M, backed by $656.6M in total assets against $228.4M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 24/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.52 – $16.89 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -18.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies cannot be mapped from source data.

Key Question #1: Can PIII sustain or expand its -18.5% operating margin and -35.0% ROIC against Medical/Nursing Services peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.46B and free cash flow of -$91.2M, how will capital allocation balance growth reinvestment against $228.4M in total debt?
Key Question #3: How sensitive is PIII's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PIII Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for P3 Health Partners Inc. (Class A) (PIII) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PIII Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 22h ago

P3 Health Partners Inc. Announces Appointment of Chief Clinical Officer

Yahoo Finance report covering P3 Health Partners Inc. (Class A) (PIII) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

P3 Health Partners Inc. Estimates – NASDAQ:PIII

TradingView report covering P3 Health Partners Inc. (Class A) (PIII) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com UK • 1d ago

P3 Health Partners names Dr. Michael Millie as chief clinical officer

Investing.com UK report covering P3 Health Partners Inc. (Class A) (PIII) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance UK • 1d ago

P3 Health Partners Inc. (PIII) Seasonal returns chart

Yahoo Finance UK report covering P3 Health Partners Inc. (Class A) (PIII) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

P3 Health Partners (PIII) Jumps 7.46% to $4.18 as Buyers Reclaim Short-Term Momentum - Option Breadth

https://www.dars.gov.et/ report covering P3 Health Partners Inc. (Class A) (PIII) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

agilon health, inc. (AGL) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering P3 Health Partners Inc. (Class A) (PIII) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.siam.in/ • 1d ago

Fortress Biotech Preferred (FBIOP) Jumps 7.35% to $18.10 as Buyers Press Toward Resistance - TRIN Signal

https://www.siam.in/ report covering P3 Health Partners Inc. (Class A) (PIII) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

P3 (PIII) Drops -5.05% — Key Support at $3.93 2026-10-24 - BPI Bear Confirmed

https://www.dars.gov.et/ report covering P3 Health Partners Inc. (Class A) (PIII) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PIII Bull vs. Bear Conversation Board — What's Your Call at $4.00?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PIII 🐻 33% BEARISH CONVICTION

TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $4.84 (+20.1%)

📌 Pinned Debate

Shares rose 4.22% to $4.20 with a recent Chief Clinical Officer appointment flagged as a catalyst.

Long PIII at $4.03 targeting $4.84. Shares rose 4.22% to $4.20 with a recent Chief Clinical Officer appointment flagged as a catalyst.. Institutional whale score is 3/20 and the risk/reward vs. the $1.52 52-week low is skewed heavily in favor of bulls.

SectorRotator 🐂 BULL

@MeanReversion_88 Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Nursing Services. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $3.26 (-19.1%)

Spot @ $4.03

Negative ROIC of -35%, Altman Z of 0.2, and Piotroski F of 1/9 signal forensic balance-sheet and cash-generation risk.

Here is the bear case nobody on the bull side wants to address on PIII: Negative ROIC of -35%, Altman Z of 0.2, and Piotroski F of 1/9 signal forensic balance-sheet and cash-generation risk.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Nursing Services triggers a 12-15% air pocket.